Option chain shows key data for Nexalin Technology's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nexalin Technology.

Nexalin Technology (NASDAQ:NXLIW) Stock, Option Chain

Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Biotech

News

Health Care

Exclusives

General

NXLIW

Nexalin says the study published in the Journal of Alzheimer&#39;s Disease shows DIFS may enhance cognition in mild Alzheimer&#39;s patients.

EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer&#39;s Patients (UPDATED)

Market-Moving Exclusives

Nexalin Technology&#39;s clinical trial results highlight notable cognitive improvements in Alzheimer&#39;s patients using Deep Intracranial Frequency Stimulation technology. The study showed significant memory and cognition gains, increased hippocampal activity, and minimal side effects.

EXCLUSIVE: Nano-Cap Nexalin&#39;s Drug-Free Alternative For Alzheimer&#39;s Shows Improved Memory, Cognitive Function In Small Study

Nexalin Technology Inc

PLUR

Pluri Announces $6.5M Private Placement With Investor Alejandro Weinstein; Co. Will Purchase ~71% Of Kokomodo's Shares

WIIM

Shares of airline stocks are trading lower following weak guidance from American Airlines.

BEAM

Beam Therapeutics To Encore Data From BEACON Phase 1/2 Clinical Trial Of BEAM-101 In Sickle Cell Disease At Tandem Meetings Of ASTCT And CIBMTR

Raymond James analyst Steve Moss upgrades First Community (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCCO#NASDAQ">FCCO</a>) from Outperform to Strong Buy and raises the price target from $27 to $30.

Upgrades

Price Target

Analyst Ratings

FCCO

Raymond James Upgrades First Community to Strong Buy, Raises Price Target to $30

On Wednesday, January 22, U.S. markets closed higher, with the S&amp;P 500 reaching a record high as Netflix gained significantly after reporting record subscribers and announcing price increases. Technology stocks, driven by AI leaders like Nvidia and Microsoft, led gains. Despite unclear funding details, investors were optimistic about President Trump&#8217;s private-sector AI investment plan.
In economic data, U.S. mortgage applications increased slightly from the prior week during the week ending January 17.
Most S&amp;P 500 sectors declined, but information technology and communication services stocks closed higher, defying the overall trend.
The Dow Jones Industrial Average was up 0.30% and closed at 44,156.73, the S&amp;P 500 closed higher by 0.61% at 6,086.37, and the Nasdaq Composite rose 1.28% to finish at 20,009.34.
Aisa Markets Today
<ul>
<li>On Thursday, Japan&#8217;s Nikkei 225 closed higher by 0.98% at 40,003.50, led by gains in the Precision Instruments, Communication, and Non-Metal Minerals sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 declined 0.61%, ending the session at 8,378.70, led by losses in the Metals &amp; Mining, Consumer Discretionary, and Materials sectors.</li>
<li>India&#8217;s Nifty 50 closed higher by 0.25% at 23,213.75, and the Nifty 500 rose 0.65%, closing at 21,536.10, led by gains in the Consumer Durables, Real Estate, and Technology sectors.</li>
<li>China&#8217;s Shanghai Composite gained 0.51% and closed at 3,230.16, and the Shenzhen CSI 300 rose 0.18%, finishing the day at 3,803.74.</li>
<li>Hong Kong&#8217;s Hang Seng closed the session lower by 0.40% at 19,700.56.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 was down 0.06%.</li>
<li>Germany&#8217;s DAX rose 0.24%.</li>
<li>France&#8217;s CAC was up 0.23%.</li>
<li>U.K.&#8217;s FTSE index 100 traded lower by 0.06%.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.19% at $75.31/bbl, and Brent was down 0.14% at $78.91/bbl.</li>
<li>Oil prices remained steady, weighed down by uncertainty over U.S. tariffs, energy policies, and rising crude inventories.</li>
<li>Natural Gas declined 0.45% to $3.942.</li>
<li>Gold was trading lower by 0.54% at $2,756.10, Silver was down 1.00% to $31.105, and Copper fell 0.42% to $4.2380.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were up 0.05%, S&amp;P 500 futures fell 0.17% and Nasdaq 100 futures declined 0.49%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. Dollar Index declined 0.07% to 108.18, USD/JPY fell 0.11% to 156.32, and USD/AUD gained 0.07% to 1.5951.</li>
<li>The dollar traded within tight ranges on Thursday, lacking direction amid uncertainty over President Trump&#8217;s U.S. tariff announcements.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Equities

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Mixed; Dollar Index Ticks Lower - Global Markets Today While US Slept

"Under the terms of the MOU, IonQ plans to provide quantum computing cloud services, support the planning and execution of joint quantum initiatives, and contribute to the workforce and economic development of South Korea. In turn, the Busan Metropolitan Government will help create an environment conducive to the growth of the quantum technology sector."

IONQ

IonQ Signs MoU With The Busan Metropolitan Government in South Korea; Co. Plans To Provide Quantum Computing Cloud Services And Support Quantum Initiatives

The investment marks an important milestone in Visa's commitment to advancing financial inclusion and shaping the future of digital payments while fostering SME growth across Africa.

Nigeria's Moniepoint Secures Investment From Visa; No Terms Disclosed

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) with a Buy and raises the price target from $4 to $6.

Reiteration

PGEN

HC Wainwright & Co. Reiterates Buy on Precigen, Raises Price Target to $6

Earnings

CLST

Catalyst Bancorp Q4 2024 GAAP EPS $0.16 Up From $0.08 YoY, Sales $2.81M Up From $2.63M YoY

Raymond James analyst Andrew Marok downgrades Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) from Outperform to Market Perform.

Downgrades

Raymond James Downgrades Electronic Arts to Market Perform

VEEV

Veeva, Zifo Announce Product Partnership To Help Biopharmas Modernize Quality Control Operations

West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTBA#NASDAQ">WTBA</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.40 by 5 percent. This is a 55.56 percent increase over earnings of $0.27 per share from the same period last year.

Earnings Beats

WTBA

West Bancorp Q4 2024 GAAP EPS $0.42 Beats $0.40 Estimate

Raymond James analyst Daniel Magder initiates coverage on Electrovaya (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVA#NASDAQ">ELVA</a>) with a Strong Buy rating and announces Price Target of $4.5.

Initiation

ELVA

Raymond James Initiates Coverage On Electrovaya with Strong Buy Rating, Announces Price Target of $4.5

Rockwell Automation Expands Advanced Technology Team By Opening New Research Lab In Prague, Czech Republic

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) with a Buy and maintains $50 price target.

GMAB

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target

IDXX

IDEXX Reports Launch Of IDEXX Cancer Dx, A Diagnostic Panel With Early Detection Of Lymphoma In Dogs

Cannabis

Markets

Aurora Cannabis Has Launched Its First German-cultivated Medical Cannabis Product, Under The Brand IndiMed, Manufactured At Aurora's Facility In Leuna, Germany

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) with a Buy and maintains $4 price target.

HOTH

HC Wainwright & Co. Reiterates Buy on Hoth Therapeutics, Maintains $4 Price Target

<h3>Gainers</h3>
<ul>
<li>Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) shares rose 11.6% to $5.85 during Thursday's pre-market session. The company's market cap stands at $42.6 million. </li>
<li>Society Pass (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) shares increased by 7.56% to $1.28. The market value of their outstanding shares is at $4.6 million. </li>
<li>System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) shares rose 5.41% to $0.94. The company's market cap stands at $66.3 million. </li>
<li>Asset Entities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) shares rose 5.14% to $1.43. The company's market cap stands at $12.4 million. </li>
<li>VS Media Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) shares rose 4.76% to $1.32. The market value of their outstanding shares is at $6.0 million. </li>
<li>Sify Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) stock moved upwards by 4.3% to $3.39. The market value of their outstanding shares is at $1.4 billion. The company's, Q3 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DallasNews (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) stock decreased by 21.8% to $5.21 during Thursday's pre-market session. The market value of their outstanding shares is at $27.8 million. </li>
<li>Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) stock decreased by 15.0% to $121.0. The market value of their outstanding shares is at $31.9 billion. </li>
<li>AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) stock decreased by 14.23% to $19.29. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Star Fashion Culture (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STFS#NASDAQ">STFS</a>) stock fell 10.99% to $2.35. The market value of their outstanding shares is at $28.5 million. </li>
<li>Snail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAL#NASDAQ">SNAL</a>) stock fell 6.19% to $2.73. The market value of their outstanding shares is at $100.8 million. </li>
<li>MediaCo Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDIA#NASDAQ">MDIA</a>) shares fell 5.67% to $1.0. The company's market cap stands at $46.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ASST

ASTS

DALN

MDIA

SIFY

SNAL

SOPA

STFS

VSME

12 Communication Services Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock moved upwards by 35.2% to $0.8 during Thursday's pre-market session. The market value of their outstanding shares is at $6.5 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares rose 25.92% to $0.17. The company's market cap stands at $1.1 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares moved upwards by 23.52% to $12.81. The market value of their outstanding shares is at $38.9 million. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) stock rose 23.15% to $2.5. The market value of their outstanding shares is at $102.1 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares moved upwards by 17.54% to $1.34. The market value of their outstanding shares is at $3.6 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares moved upwards by 15.2% to $2.5. The company's market cap stands at $130.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock declined by 8.4% to $0.24 during Thursday's pre-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) stock declined by 7.62% to $20.15. The market value of their outstanding shares is at $354.9 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares fell 7.42% to $0.59. The company's market cap stands at $30.2 million. </li>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares declined by 7.04% to $2.51. The company's market cap stands at $15.1 million. </li>
<li>Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) stock declined by 6.62% to $13.7. The market value of their outstanding shares is at $947.5 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock declined by 6.43% to $6.99. The market value of their outstanding shares is at $75.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZTR

CHRO

ELTX

ERNA

HEPA

QNRX

RIGL

TNFA

VIGL

XCUR

ZYME

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Press Releases

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Nexalin Technology Announces Landmark Study on Alzheimer's Disease  and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nexalin Technology CEO Provides Letter to Shareholders

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025

Comments

Nexalin Technology

Nexalin Technology (NXLIW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga